'Hbeag positive' presentation slideshows

HBV Factors and Clinical Outcomes M Omata

HBV Factors and Clinical Outcomes M Omata. Genotypes in China and Japan. West Asia. North East Asia. Miyakawa Y et al. Intervirology 2003. North East Asia. B and C. D. West Asia. Any Difference Between B and C. Born Infected. Natural Course HBV Infection. HBeAg-positive. ALT.

489 views • 39 slides

HIV Grand Round F2

506 views • 37 slides

430 views • 36 slides

Samuel S. Lee University of Calgary Calgary, Canada

3 rd Paris Hepatitis Congress, 20/1/09 HBeAg-positive patient: Why do I treat with nucleos/tide analogs?. Samuel S. Lee University of Calgary Calgary, Canada. Speaker declarations.

344 views • 34 slides

Chronic Hepatitis B Evaluation and Management

457 views • 24 slides

Geoffrey DUSHEIKO

Geoffrey DUSHEIKO. Nucleosides for HBeAg-positive chronic hepatitis B. G Dusheiko Centre for Hepatology Royal Free and University College School of Medicine London UK. Nucleosides for HBeAg positive chronic hepatitis B. Discuss Efficacy Safety Utility Resistance outstanding questions.

246 views • 24 slides

Prevalence of Hepatitis B infection in married women of child bearing age in District Islamabad

298 views • 18 slides

Hepatitis B

663 views • 17 slides

Hepatitis B

763 views • 17 slides

GLOBE: Efficacy at Year 2, HBeAg-Positive Patients ITT Population

GLOBE: Efficacy at Year 2, HBeAg-Positive Patients ITT Population. *designates P <0.05, telbivudine vs lamivudine at Week 104. Adapted from AASLD 2006. GLOBE: Viral Load/Resistance at 24 Weeks. HBeAg Positive. HBeAg Negative. 100. 90. Telbivudine Lamivudine. 80. 70. 60. 56. 60. 50.

144 views • 2 slides